Eli Lilly follows JNJ in suing govt. over 340B drug-discount program
Eli Lilly (NYSE:LLY) has filed a lawsuit over a U.S. health agency's alleged attempts to block its model for offering rebates for drugs supplied under the government's 340B Program, days after its rival Johnson & Johnson (NYSE:JNJ) filed a similar lawsuit.
Eli Lilly, J&J Sue US Over Rejected Changes To Drug Discounting Program
Eli Lilly became the second drugmaker this week to sue the U.S. government for rejecting their proposed changes to a program that requires selling discounted drugs to certain medical facilities.
Lilly sues US agency over blocking of drug-rebate program
Eli Lilly said on Thursday it sued the federal Health Resources and Services Administration (HRSA) over allegedly blocking the company's plan to change the way it offers drug discounts to hospitals.
Lilly Sues US Agency For Blocking Proposed Drug Rebate Plan
Eli Lilly sued the Health Resources and Services Administration (HRSA) for allegedly blocking the pharma giant's proposal to change the manner by which it offers discounts on medicines under the 340B program.
Lilly Sues U.S. to Change Hospital Drug Discount Payments
The lawsuit is the second by a large drugmaker in recent days challenging how it provides required discounts to certain hospitals.
Mounjaro-Maker Eli Lilly Files Lawsuit Against US Agency Over Drug Rebate Program
Eli Lilly proposed a plan to ensure 340B entities pay no more than the ceiling price by providing them with cash directly on a weekly basis.
Eli Lil­ly sues the US gov­ern­ment over its pro­posed 340B re­bate mod­el
Eli Lil­ly is now the sec­ond drug­mak­er to pro­pose a re­bate mod­el for 340B drug price dis­counts — and the sec­ond to sue over it. … Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
J&J sues HRSA for blocking controversial 340B rebate plan
Johnson & Johnson is escalating its fight with the federal government over its controversial plan to change how it doles out drug discounts to hospitals. | Johnson & Johnson is escalating its fight with the federal government over its controversial plan to change how it doles out drug discounts to hospitals.
STAT1d
Pharmalittle: We’re reading about an Alzheimer’s drug about-face, Bavarian Nordic’s views on Trump, and more
Reversing an earlier decision, European regulators recommended that the Alzheimer’s therapy Leqembi should be approved ...
Modern Healthcare1d
340B drug rebate proposal leads to another lawsuit
Eli Lilly contends it should be allowed to vet data from 340B hospitals before providing rebates, rather than offer upfront ...
Becker's Hospital Review1d
Lilly sues feds to allow 340B changes: 5 details
Lilly filed a lawsuit Nov. 14 against HHS head Xavier Becerra and the Health Resources and Services Administration for blocking a plan to change its 340B program from immediate discounts to offering ...
Healthcare Dive3d
J&J sues federal government for halting 340B rebate plan
This summer, J&J unveiled a plan to give hospitals after-the-fact rebates for two medications in the program, called 340B, instead of upfront discounts, but paused implementation following threats ...